Guggenheim Maintains Buy on Travere Therapeutics, Raises Price Target to $54

Benzinga Newsdesk www.benzinga.com Positive 83.8%

Neg 0% Neu 0% Pos 83.8%

Guggenheim analyst Vamil Divan maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $49 to $54.